105 related articles for article (PubMed ID: 16859287)
1. Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects.
Klekota J; Brauner E; Roth FP; Schreiber SL
J Chem Inf Model; 2006; 46(4):1549-62. PubMed ID: 16859287
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds.
Peters JU; Schnider P; Mattei P; Kansy M
ChemMedChem; 2009 Apr; 4(4):680-6. PubMed ID: 19266525
[TBL] [Abstract][Full Text] [Related]
3. PASS: identification of probable targets and mechanisms of toxicity.
Poroikov V; Filimonov D; Lagunin A; Gloriozova T; Zakharov A
SAR QSAR Environ Res; 2007; 18(1-2):101-10. PubMed ID: 17365962
[TBL] [Abstract][Full Text] [Related]
4. Deriving knowledge through data mining high-throughput screening data.
Diller DJ; Hobbs DW
J Med Chem; 2004 Dec; 47(25):6373-83. PubMed ID: 15566306
[TBL] [Abstract][Full Text] [Related]
5. Modeling promiscuity based on in vitro safety pharmacology profiling data.
Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
[TBL] [Abstract][Full Text] [Related]
6. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
[TBL] [Abstract][Full Text] [Related]
7. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation.
Dai WG; Pollock-Dove C; Dong LC; Li S
Adv Drug Deliv Rev; 2008 Mar; 60(6):657-72. PubMed ID: 18222563
[TBL] [Abstract][Full Text] [Related]
8. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
9. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs.
Hu Y; Bajorath J
J Chem Inf Model; 2010 Dec; 50(12):2112-8. PubMed ID: 21070069
[TBL] [Abstract][Full Text] [Related]
10. Structure-based maximal affinity model predicts small-molecule druggability.
Cheng AC; Coleman RG; Smyth KT; Cao Q; Soulard P; Caffrey DR; Salzberg AC; Huang ES
Nat Biotechnol; 2007 Jan; 25(1):71-5. PubMed ID: 17211405
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Vitotox and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development.
Westerink WM; Stevenson JC; Lauwers A; Griffioen G; Horbach GJ; Schoonen WG
Mutat Res; 2009 May; 676(1-2):113-30. PubMed ID: 19393335
[TBL] [Abstract][Full Text] [Related]
12. Learning from the data: mining of large high-throughput screening databases.
Yan SF; King FJ; He Y; Caldwell JS; Zhou Y
J Chem Inf Model; 2006; 46(6):2381-95. PubMed ID: 17125181
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
[TBL] [Abstract][Full Text] [Related]
14. In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates.
Olaharski AJ; Uppal H; Cooper M; Platz S; Zabka TS; Kolaja KL
Toxicol Lett; 2009 Jul; 188(2):98-103. PubMed ID: 19446241
[TBL] [Abstract][Full Text] [Related]
15. Shannon entropy-based fingerprint similarity search strategy.
Wang Y; Geppert H; Bajorath J
J Chem Inf Model; 2009 Jul; 49(7):1687-91. PubMed ID: 19583222
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Integration of fragment screening and library design.
Siegal G; Ab E; Schultz J
Drug Discov Today; 2007 Dec; 12(23-24):1032-9. PubMed ID: 18061882
[TBL] [Abstract][Full Text] [Related]
18. Identifying biologically active compound classes using phenotypic screening data and sampling statistics.
Klekota J; Brauner E; Schreiber SL
J Chem Inf Model; 2005; 45(6):1824-36. PubMed ID: 16309290
[TBL] [Abstract][Full Text] [Related]
19. Chemogenomics approaches to novel target discovery.
Gaither LA
Expert Rev Proteomics; 2007 Jun; 4(3):411-9. PubMed ID: 17552925
[TBL] [Abstract][Full Text] [Related]
20. Fragment-based activity space: smaller is better.
Hesterkamp T; Whittaker M
Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
